With its silence on key questions, Omeros raises doubts about its rare disease drug

The Seattle biotech Omeros has long told investors it has a potential blockbuster for rare diseases, but it won't answer key questions about clinical data.

The Seattle biotech Omeros (OMER) has long told investors it has a potential blockbuster on its hands in OMS721, an experimental drug aimed at treating patients with rare blood and kidney diseases.

So why won’t the company answer questions about its clinical data?

I’ve been trying for months to get answers on key points: How many patients have been dosed with the drug in clinical trials? And is there any proof at all that the drug can be administered via subcutaneous injection, rather than intravenous drip — which is a key selling point for Omeros?

I’ve been met with total silence. That leads me to believe that Omeros may have oversold the drug, which it pitches as a potential competitor to Soliris, a), hit almost $3 billion worldwide last year — and much of Omeros’ $1 billion valuation comes from investors hoping that OMS721 can be a viable competitor.

You're reading a preview, sign up to read more.

More from STAT

STAT1 min readWellness
STAT Plus: Pharmalittle: France Piles Pressure On Sanofi Over Covid-19 Vaccine; GOP Fails To Land A Punch On Bright
Under an “America First” president, public health experts worry the U.S. could seek to gobble up early supplies of Covid-19 vaccine.
STAT1 min readSociety
STAT Plus: Pharmalittle: Coronavirus Vaccine May Not Be A Cure-all; Hydroxychloroquine Fails In A Covid-19 Study
#Covid19 vaccines in development may be more like those that protect against influenza — reducing the risk of contracting the disease and of experiencing severe symptoms should infection occur.
STAT1 min readWellness
STAT Plus: Pharmalittle: Administration Mishandled Initial Remdesivir Distribution; AstraZeneca Lung Cancer Drug Shows Big Benefit
The Trump administration mishandled the initial distribution of remedesivir, the experimental Gilead Sciences Covid-19 medicine, delaying treatment to some critically ill patients.